Active not recruiting

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

I4T-MC-JVDL - ClinicalTrials.gov - NCT02789345

The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).
How long will I be in the trial?
The duration of your participation will depend on the duration of your study treatment, your disease progression, and follow-up visits
Email
Active not recruiting

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

I4T-MC-JVDL - ClinicalTrials.gov - NCT02789345

The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).
How long will I be in the trial?
The duration of your participation will depend on the duration of your study treatment, your disease progression, and follow-up visits
Email

Key Requirements

Age :

18+

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have a diagnosis of NSCLC with at least 1 measurable lesion

Participants must NOT

Participant must not have had previous treatment with osimertinib or third generation EGFR TKIs

Participant must not have experienced a heart attack, unstable angina, or stroke, within 6 months prior to enrollment

Participant must not have a history of deep vein thrombosis, pulmonary embolism, or any other significant venous thromboembolism during the 3 months prior to study enrollment

Participant must not have a bowel obstruction, Crohn's disease, ulcerative colitis, chronic diarrhea or a history of gastrointestinal perforation and/or fistula within 6 months prior to enrollment

Participant must not have uncontrolled hypertension

Participant must not be receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy or radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks prior to enrollment

Trial Summary

Conditions the trial is for

Non-small Cell Lung Cancer

What the trial is testing?

Ramucirumab (LY3009806) + Osimertinib, Necitumumab (LY3012211) + Osimertinib

Could I receive a Placebo?

no

Enrollment Goal

74

Trial Dates

October 2016 - May 2021

Trial Phase

1

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participant must have a diagnosis of NSCLC with at least 1 measurable lesion

Participants must NOT

Participant must not have had previous treatment with osimertinib or third generation EGFR TKIs

Participant must not have experienced a heart attack, unstable angina, or stroke, within 6 months prior to enrollment

Participant must not have a history of deep vein thrombosis, pulmonary embolism, or any other significant venous thromboembolism during the 3 months prior to study enrollment

Participant must not have a bowel obstruction, Crohn's disease, ulcerative colitis, chronic diarrhea or a history of gastrointestinal perforation and/or fistula within 6 months prior to enrollment

Participant must not have uncontrolled hypertension

Participant must not be receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy or radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks prior to enrollment

Trial Summary

Conditions the trial is for

Non-small Cell Lung Cancer

What the trial is testing?

Ramucirumab (LY3009806) + Osimertinib, Necitumumab (LY3012211) + Osimertinib

Could I receive a Placebo?

no

Enrollment Goal

74

Trial Dates

October 2016 - May 2021

Trial Phase

1

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Non-small Cell Lung Cancer Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?